By Tony Fong

NEW YORK (GenomeWeb News) – Even before whole-genome sequencing becomes a reality in the clinical setting, one Los Angeles-based firm is betting its future on the promise of the technology.

To hear Existence Genetics Founder and CEO Brandon Colby tell it, whole-genome sequencing is only two years away from widespread clinical applicability, and when that day arrives, Existence will be ready to pounce on the market opportunity.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.